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Abstract
Regulated differentiation of chondrocytes is essential for both
normal skeletal development and maintenance of articular
cartilage. The intracellular pathways that control these events
are incompletely understood, and our ability to modulate the
chondrocyte phenotype in vivo or in vitro is therefore limited.
Here we examine the role played by one prominent group of
intracellular signalling proteins, the Src family kinases, in
regulating the chondrocyte phenotype. We show that the Src
family kinase Lyn exhibits a dynamic expression pattern in the
chondrogenic cell line ATDC5 and in a mixed population of
embryonic mouse chondrocytes in high-density monolayer
culture. Inhibition of Src kinase activity using the
pharmacological compound PP2 (4-Amino-5-(4-chlorophenyl)-
7-(t-butyl)pyrazolo [3,4-d]pyrimidine) strongly reduced the
number of primary mouse chondrocytes. In parallel, PP2
treatment increased the expression of both early markers (such
as Sox9, collagen type II, aggrecan and xylosyltransferases) and
late markers (collagen type X, Indian hedgehog and p57)
markers of chondrocyte differentiation. Interestingly, PP2
repressed the expression of the Src family members Lyn, Frk
and Hck. It also reversed morphological de-differentiation of
chondrocytes in monolayer culture and induced rounding of
chondrocytes, and reduced stress fibre formation and focal
adhesion kinase phosphorylation. We conclude that the Src
kinase inhibitor PP2 promotes chondrogenic gene expression
and morphology in monolayer culture. Strategies to block Src
activity might therefore be useful both in tissue engineering of
cartilage and in the maintenance of the chondrocyte phenotype
in diseases such as osteoarthritis.
Introduction
Chondrocytes are the only cell type in cartilage and are pre-
dominantly derived from mesenchymal precursor cells. Tight
regulation of chondrocyte differentiation is essential both for
normal skeletal development and growth, and for the mainte-
nance of joint health (for example, the prevention of degenera-
tive diseases such as osteoarthritis [OA]). The majority of our
skeleton develops through the process of endochondral ossi-
fication, which starts with the formation of a cartilage template
[1-3]. Within this template, chondrocyte proliferation, differen-
tiation (hypertrophy) and apoptosis are precisely regulated,
resulting in endochondral bone growth and ultimately replace-
ment of cartilage by bone tissue. Gene mutations and other
factors that disturb the normal maturation pattern of chondro-
cytes generally result in chondrodysplasias and other forms of
dwarfism and skeletal deformities [4]. Strict control of the
chondrocyte phenotype is also required to maintain the func-
tion of the articular cartilage and to prevent cartilage degrada-
tion in diseases such as OA. Both loss of the differentiated
phenotype and ectopic hypertrophic differentiation are
thought to contribute to OA progression [5-7].
Marker genes for chondrocytes of different maturation stages
have been identified. Proliferating and articular chondrocytes
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exhibit fairly similar gene expression patterns; for example,
both express Sox9 (a transcription factor that is absolutely
necessary for chondrocyte differentiation), the related factors
L-Sox5 and Sox6, and collagen type II and aggrecan. Addition-
ally, differentiating chondrocytes produce glycosaminoglycans
that are attached to proteoglycans such as aggrecan by
xylosyltransferases 1 and 2 (encoded by the Xylt1 and Xylt2
genes, respectively) [8-10]. Glycosaminoglycans require sul-
phation for function, a step that is catalyzed by chondroitin sul-
photransferases. In cartilage, chondroitin 6 sulphotransferase
(encoded by Chst3) and chondroitin 4 sulphotransferase
(Chst11) are of particular importance, as documented by the
consequences of mutations in these genes in humans or mice
[11,12]. We demonstrated regulation of both xylosyltrans-
ferase and chondroitin sulphotransferase genes during chon-
drogenesis [13,14]. In contrast to these markers of early
chondrogenesis, postmitotic and hypertrophic chondrocytes
express many different genes, including those encoding colla-
gen type X and the secreted signalling protein Indian hedge-
hog [4,15,16].
A greater understanding of the mechanisms that control
chondrocyte differentiation is required so that we may design
efficient strategies to treat skeletal growth disorders, to pre-
vent loss of cartilage in OA and to generate new cartilage in
tissue engineering approaches. In particular, loss of the
chondrocyte phenotype has been observed both during in
vitro  culture [17-20], complicating tissue engineering
approaches to generate cartilage, and during the development
of OA in vivo [6,21]. However, the signalling pathways that
control chondrocyte physiology are only incompletely under-
stood. Tyrosine kinases form one major group of signalling
proteins in eukaryotes and can be further divided into two
classes [22,23]: the receptor tyrosine kinases and the nonre-
ceptor tyrosine kinases. The former are cell surface receptors
for extracellular ligands such as growth factors. Several of
them, most notably fibroblast growth factor receptor 3 [24],
have been shown to play important roles in chondrocytes. In
contrast, very little is known about the function of nonreceptor
tyrosine kinases in cartilage. This study focuses on one prom-
inent family within this class, the Src kinases.
The Src family consists of 11 members that have been impli-
cated in many cellular functions, including cell proliferation, dif-
ferentiation, apoptosis and migration [25,26]. Most
mammalian cells express multiple family members with over-
lapping functions. The resulting redundancy has created prob-
lems in investigating the function of individual Src kinase family
members, because genetic inactivation (for example, in knock-
out mice) of individual members has often yielded surprisingly
mild phenotypes. To overcome this problem, Src family func-
tion is often studied using PP2 (4-Amino-5-(4-chlorophenyl)-
7-(t-butyl)pyrazolo [3,4-d]pyrimidine), a pharmacological com-
pound that inhibits all Src kinases [27,28]. In this study, we
employed PP2 to examine the effects of Src inhibition on
chondrocyte differentiation. We specifically considered
whether and how PP2 would affect parameters of the
chondrocyte phenotype, such as chondrogenic morphology,
actin organization and gene expression.
Materials and methods
Cell culture
ATDC5 cells were cultured in media consisting of 47.5% Dul-
becco's modified essential medium, 47.5% F12, 5% foetal
bovine serum, 0.25% L-glutamine and 0.25% Penstrep (Invit-
rogen, Burlington, Ontario, Canada), and induced to differen-
tiate with 1% ITS (Sigma, Oakville, Ontario, Canada), as
described previously [29,30]. Cells for RNA isolation were
plated in six-well plates (Falcon) at a density of 60,000 cells/
well.
For primary chondrocyte cultures, embryos were dissected
from CD1 timed-pregnant mice (Charles River Laboratories,
St. Constant, Quebec, Canada) at embryological day 15.5,
and chondrocytes were isolated from long bones, as
described previously [31,32], by sequential digestion with
trypsin and collagenase. Cells were re-suspended in media
consisting of 55% F12, 35% Dulbecco's modified essential
medium and 10% foetal bovine serum, and supplemented with
0.25% L-glutamine and 0.25% Penstrep (Invitrogen). The pri-
mary chondrocytes were then plated according to the desired
use. For RNA and protein isolation, chondrocytes were plated
in six-well plates (Falcon) at 500,000 cells per well. Primary
chondrocyte cultures were treated with 1 μmol/l or 10 μmol/l
of the Src family kinase inhibitor PP2 (Calbiochem; VWR, Mis-
sissauga, Ontario, Canada) or with dimethyl sulphoxide
(DMSO; Sigma), the vehicle in which PP2 was dissolved, as
control. For other experiments, primary chondrocytes were
cultured as described above and treated with 10 μmol/l
Y27632, 1 μmol/l cytochalasin D, 50 nmol/l jasplakinolide, or
the vehicle DMSO.
Taqman real-time PCR
Total RNA was harvested from treated cultures on days 3, 6,
9, 12, 15, and 18 of ATDC5 differentiation, as well as from pri-
mary chondrocyte cultures treated with DMSO, PP2, cytoch-
alasin D, Y27632, or jasplakinolide. RNA was isolated using a
Qiagen (Mississauga, Ontario, Canada) RNeasy kit, following
the manufacturer's instructions. RNA samples were diluted to
a final concentration of 25 ng/μl for use in real-time RT-PCR,
as described previously [33]. Relative gene expression was
measured using Assays on Demand (Applied Biosystems) for
Col2a1, Col10a1, Agc1, Sox6, Sox5, Sox9, Chst3, Chst11,
Xylt1, Xylt2, Ihh, Cdkn1c, Atf3, Lyn, Frk, and Hck in relation to
the glyceraldehyde-3-phosphate dehydrogenase gene
(Gapdh; Applied Biosystems, Foster City, CA, USA) using
One Step RT qPCR Master Mix Plus (Eurogentec North Amer-
ica, San Diego, CA, USA) and 40 cycles on the ABI Prism
7900 HT sequence detector (PerkinElmer, Emeryville, CA,
USA). Real-time analysis was performed as quadruplicateAvailable online http://arthritis-research.com/content/9/5/R105
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reactions on at least three independent trials in each experi-
mental situation.
Western blotting
Protein was harvested from primary cell cultures using RIPA
lysis buffer (150 nmol/l NaCl, 50 mmol/l Tris-HCl [pH 7.5], 1%
Triton-X, 1% deoxycholate, 0.1% SDS, 2 mmol/l EDTA) sup-
plemented with a protease inhibitor mini complete tablet
(Roche Applied Science, Laval, Quebec, Canada). The iso-
lated protein was then sonicated and quantified with the Bicin-
choninic Acid kit (Sigma), in accordance with the
manufacturer's protocol. An equal quantity (20 μg) of each
sample was used in SDS-PAGE and transferred to nitrocellu-
lose membrane (BioRad Labratories, Mississauga, Ontario,
Canada). Membranes were then blocked in 5% bovine serum
albumin (BSA) in Tris-buffered saline with 0.01% Tween-20
(TBST), followed by overnight incubation at 4°C with primary
antibody against Lyn (Cell Signaling Technology, Inc., Missis-
sauga, Ontario, Canada) or β-actin (Sigma) diluted 1:200 in
5% bovine serum albumin-TBST. Blots were then washed
three times for 5 minutes in TBST, followed by incubation with
the appropriate HRP (horseradish peroxidase)-conjugated
secondary antibody (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) for 1 hour at 4°C. Membranes were then washed
three times for 5 minutes in TBST before detection of proteins
by ECL Western Blot detection reagents (Amersham Bio-
science, Oakville, Ontario, Canada), in accordance with the
manufacturer's instructions. Banding on the membranes was
visualized using a ChemiImager 5500 (AlphaInnotech Inc.,
San Leandro, CA, USA). Western blotting was performed on
samples from three independent trials.
MTT assays
Cellular proliferation was determined using an MTT Cell Prolif-
eration Kit I (Roche Applied Science), which had been tested
and confirmed as a valid method for quantifying chondrocyte
cell number in our laboratory [29,34]. Primary chondrocytes
were plated on 96-well plates at a density of 10,000 cells/well
and treated with 1 μmol/l or 10 μmol/l of the tyrosine kinase
inhibitor Tyr A23, Tyr A25, or Tyr A47, or the Src family kinase
inhibitor PP2, or with DMSO alone as the vehicle control. In
accordance with the manufacturer's directions, cells were
treated with MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl
tetrazolium bromide) at 24, 48 and 72 hours and, following
incubation and solubilization, absorbance was measured at
600 nm with a spectrophotometer as described previously
[35]. MTT assays were performed in four independent trials.
Immunofluorescence
Primary chondrocytes were plated on glass coverslips in a 24-
well plate at a density of 50,000 cells/well and cells were
allowed to adhere overnight. The following morning, cells were
treated either with 10 μmol/l PP2 or DMSO as a control and
incubated for an additional 24 hours. The next day, cells were
freshly treated with the inhibitor or vehicle alone. After a 1-hour
incubation period, cells were washed with room temperature
phosphate-buffered saline (PBS) and fixed with 4% parafor-
maldehyde in PBS for 10 minutes. After rinsing with fresh
PBS, cells were incubated with 0.1% Triton-X solution in PBS
for 5 minutes to allow for membrane permeability. The cover-
slips were then rinsed in PBS and incubated in blocking solu-
tion (1:20 goat serum [Sigma]:PBS) for 30 minutes at room
temperature. After blocking, primary antibody against FAK
(BioSource International, Inc.) or phospho-FAK [pY397] (Bio-
Source International, Inc., Montreal, Quebec, Canada; 1:100
antibody:blocking solution) was added to the coverslips and
incubated for 45 minutes at room temperature. After washing
with PBS, the coverslips were incubated for 45 minutes in the
dark at room temperature with a fluorescein isothionate-conju-
gated secondary antibody diluted 1,000 times in PBS. Cover-
slips were again washed before incubation with rhodamine-
phalloidin solution (Cytoskeleton, Denver, CO, USA) for 45
minutes in a dark environment. Following incubation, the cov-
erslips were rinsed and mounted using VectaShield with DAPI
(Vector Laboratories Inc., Burlingane, CA, USA). Images of
these cells were taken with a Leica DMRA2 fluorescence
microscope (Quorum Technologies, Guelph, Ontario, Can-
ada) at 63-fold magnification and analyzed using OpenLab
software. (Quorum Technologies, Guelph, Ontario, Canada).
Fluorescence imaging was performed on at least three inde-
pendent trials.
RhoA activity assay
Primary chondrocytes were cultured with DMSO or PP2 for 1
to 3 days. Ras homology A (RhoA) activity was measured
using a luminescent G-LISA™ kit (Cytoskeleton), as described
previously [36].
Statistical analyses
All experiments were performed in at least three independent
trials. Real-time PCR data represent an average of three inde-
pendent trials of samples run in quadruplicate, normalized to
Gapdh and to day control (DMSO) levels. Statistical signifi-
cance was determined using a one-way analysis of variance
with Bonferroni's post-test (P < 0.05). Statistical tests were
performed using GraphPad Prism version 4.00 for Windows
(GraphPad Software, San Diego, CA, USA).
Results
Dynamic expression of Lyn during chondrocyte 
differentiation
We first examined the expression of Src family members in a
microarray dataset derived from embryonic limb bud mesen-
chymal cells undergoing chondrogenic differentiation in micro-
mass culture [37]. The Lyn,  Hck  and  Frk  genes exhibited
significant expression during chondrocyte differentiation and
were chosen for further study. The ATDC5 cell line has been
shown to undergo the entire process of chondrocyte differen-
tiation when treated with insulin [38,39]. Real-time PCR dem-
onstrated that Lyn expression increased strongly throughoutArthritis Research & Therapy    Vol 9 No 5    Bursell et al.
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ATDC5 differentiation (Figure 1a). In contrast, Frk and Hck
transcript levels underwent relatively minor changes during
ATDC5 differentiation (Figure 1b,c).
High-density monolayer cultures of primary chondrocytes iso-
lated from embryonic growth plates present a mixed popula-
tion expressing both early and late markers of chondrocyte
differentiation. Primary chondrocyte cultures are a good model
in which to study chondrocyte physiology because they are
closer to the in vivo chondrocyte phenotype than are trans-
formed cell lines. Western blotting confirmed that Lyn protein
is expressed in primary mouse chondrocytes in monolayer cul-
ture and increases over the culture period (Figure 1d).
Src inhibition decreases chondrocyte cell numbers
We next examined effects of general tyrosine kinase and Src-
specific inhibitors on numbers of primary mouse chondrocytes
using MTT assays, because our earlier studies had demon-
strated that MTT values correspond to chondrocyte cell num-
bers [29,34]. Over the 3-day time course, numbers of
chondrocytes in control cultures increased steadily. The gen-
eral tyrosine kinase inhibitors Tyr A23, Tyr A25 and Tyr A47
had minor effects on cell number at 1 μmol/l concentration,
but they caused a significant decrease in cell numbers at 10
μmol/l (Figure 2a). In comparison, the more specific com-
pound PP2 that only inhibits the Src family of tyrosine kinases
caused a much stronger reduction in cell number, in particular
Figure 1
Expression of Src kinases in chondrogenic cells Expression of Src kinases in chondrogenic cells. Expression of (a) Lyn, (b) Frk and (c) Hck Src kinase genes during chondrogenic differentiation of 
ATDC5 cells (days 3 to 18) was analyzed using Taqman real-time PCR analyses. Lyn mRNA levels increased strongly during differentiation, whereas 
the other two kinase genes exhibited more subtle changes in gene expression. (d) Western blotting confirmed expression of Lyn protein in primary 
mouse chondrocytes in monolayer culture for 1 to 3 days.Available online http://arthritis-research.com/content/9/5/R105
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at the 10 μmol/l concentration (Figure 2b). These data sug-
gest that Src kinases are required for proliferation of these
cells.
Src inhibition promotes chondrogenic gene expression
We then examined the effects of PP2 (10 μmol/l) on the
expression of chondrocyte marker genes using the same
culture system. In control cultures, levels of transcripts for the
chondrogenic master transcription factor Sox9 decreased
slightly over the culture period (Figure 3a). This downregula-
tion was prevented by PP2. mRNA levels for the related tran-
scription factors L-Sox5 and Sox6 remained constant over 3
days in control cultures but were significantly enhanced by
PP2 (Figure 3b,c). Similar trends were observed for the major
extracellular matrix genes Col2a1 (which encodes collagen
type II) and Acan (which encodes aggrecan; Figure 3d,e), but
Acan induction by PP2 was markedly greater than that of the
other genes.
Because aggrecan is the major core proteoglycan in cartilage,
we wished to determine whether PP2 affects genes that are
involved in glycosaminoglycan synthesis. Transcripts for the
xylosyltransferases were significantly increased at days 1 and
2 (Xylt1) or days 2 and 3(Xylt2) in response to Src family inhi-
bition (Figure 4a,b). Additionally, both examined chondroitin
sulphotransferase genes (Chst3  and  Chst11) were signifi-
cantly upregulated in primary chondrocyte cultures by PP2
treatment for 1 and 2 days (Figure 4c,d). However, Chst3
expression decreased by day 3 in cultures treated with PP2 in
comparison with control, whereas Chst11 levels remain ele-
vated in the presence of PP2 at day 3.
We also assessed effects of Src inhibition on markers for later
(postmitotic) stages of chondrocyte maturation. Both
Col10a1 (collagen type X) and Ihh (Indian hedgehog) mRNA
levels decreased over time in culture, but were higher upon
PP2 treatment (Figure 5a,b). Similarly, PP2 increased the
expression of transcripts for the cell cycle inhibitor p57
(Cdkn1c) and for Atf3 (Figure 5c,d), which encodes a tran-
scription factor that we have identified as being upregulated
during chondrocyte hypertrophy [31]. Thus, the expression
levels for all 13 chondrocyte marker genes examined here
were elevated in the presence of PP2.
PP2 causes reduced expression of Lyn, Frk and Hck
We considered whether PP2 also influences expression of the
Src kinase genes in chondrocytes. All three examined Src
kinase genes (Lyn, Frk and Hck) exhibited upregulation over
the 3-day culture period in control conditions (Figure 6a–c).
However, transcript levels were significantly reduced in the
presence of PP2 at all stages (with the exception of Frk at day
2). These data suggest that Src activity is required to maintain
expression of at least some family members.
Src inhibition results in cell rounding and a reduction in 
stress fibres
During our studies, we noticed that PP2 induces a marked
change in chondrocyte morphology. In monolayer culture,
chondrocytes rapidly lose their rounded/polygonal shape,
become elongated and fibroblastoid, and develop prominent
actin stress fibres (Figure 7a[20]). PP2 treatment reversed
these effects and resulted in rounded cells with a cortical actin
cytoskeleton, without stress fibres (Figure 7b). Stress fibre for-
mation correlated with the accumulation of focal adhesion
kinase (FAK) at the ends of the fibres (Figure 8a). Immunoflu-
orescence for a phosphorylated form of FAK (Y397) exhibited
a similar pattern (Figure 8c). In the presence of PP2, total FAK
showed diffuse staining (Figure 8b) and phosphorylated FAK
was no longer detectable (Figure 8d), suggesting that PP2
inhibits FAK phosphorylation.
The morphological changes that occurred upon PP2 treat-
ment resembled those we had observed when we inhibited
Rho-associated, coiled-coil containing protein kinase
(ROCK)1/2 kinases, prime effectors of the small GTPase
RhoA [20]. These data suggest that Src kinases and RhoA/
ROCK might act in the same signalling pathway. We therefore
considered whether PP2 treatment modulates RhoA activity.
Figure 2
Src kinase activity regulates chondrocyte cell numbers Src kinase activity regulates chondrocyte cell numbers. Primary mouse 
chondrocytes were incubated for 1 to 3 days with dimethyl sulphoxide 
(DMSO), (a) the general tyrosine kinase inhibitors Tyr A23, Tyr A25 
and Tyr A47, or (b) the Src inhibitor PP2 (1 and 10 μmol/l each). Cell 
numbers were determined by MTT assay. All inhibitors reduced cell 
numbers at the 10 μmol/l concentration, but the effects of PP2 were 
more pronounced (n = 4; *P < 0.01, ***P < 0.001).Arthritis Research & Therapy    Vol 9 No 5    Bursell et al.
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Primary chondrocytes were treated with PP2 for 1 to 3 days,
and RhoA activity was determined as described previously
[36]. Src inhibition did not affect RhoA activity at any stage
(Figure 9a). To determine whether ROCK signalling affects
expression of the Src kinases studied here, we analyzed Lyn,
Frk and Hck transcript levels in primary chondrocytes treated
with the ROCK inhibitor Y27632. Parallel experiments were
done with the actin-modifying drugs cytochalasin D and jas-
plakinolide, which have overlapping effects with Y27632 on
chondrocytes [20,36]. Both Lyn  and  Frk  transcripts were
Figure 3
PP2 promotes expression of early chondrocyte marker genes PP2 promotes expression of early chondrocyte marker genes. Primary mouse chondrocytes were incubated for 1 to 3 days with dimethyl sulphoxide 
(DMSO) or the Src inhibitor PP2 (10 μmol/l), and transcript levels of early chondrocyte marker genes were determined by real-time PCR. Expression 
levels of (a) Sox9, (b) Sox5, (c) Sox6, (d) Col2a1 and (e) Acan (aggrecan) were significantly increased upon Src inhibition (n = 3; **P < 0.01, ***P 
< 0.001).Available online http://arthritis-research.com/content/9/5/R105
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slightly increased in response to Y27632 and cytochalasin D
and repressed by jasplakinolide (Figure 9b,c). In contrast, Hck
transcript levels were reduced by cytochalasin D and
enhanced by jasplakinolide and Y27632 (Figure 9d).
Discussion
In this study we demonstrate that the Src inhibitor PP2
reduces proliferation, promotes chondrogenic gene expres-
sion and induces chondrogenic morphology in primary
chondrocytes in monolayer culture. These data suggest that
inhibition of Src activity could be a valid strategy to maintain or
induce the chondrocyte phenotype, for example in tissue engi-
neering approaches to in vitro cartilage formation or in the pre-
vention of cartilage loss in OA patients. Moreover, our data
suggest physiological roles for Src kinases in the regulation of
chondrogenesis.
General inhibition of tyrosine kinase activity by a variety of
compounds resulted in a mild reduction in chondrocyte cell
numbers. Our data cannot distinguish whether these effects
are due to decreased proliferation or increased cell death;
however, because these effects were observed while cell
numbers increased rapidly, a proliferative effect appears more
likely. Specific inhibition of one subgroup of tyrosine kinases,
the Src family, caused a much more marked reduction in cell
numbers. These data suggest that other tyrosine kinases
counteract the mitogenic effects of Src proteins. One likely
candidate for such a function is the receptor tyrosine kinase
fibroblast growth factor receptor 3, which is known to induce
cell cycle withdrawal in chondrocytes [24]. However, it is likely
that other promitogenic and antimitogenic tyrosine kinases
also contribute to the effects of the broad spectrum tyrosine
kinase inhibitors used here. For example, mouse knockout
Figure 4
PP2 promotes expression of genes involved in glycosaminoglycan synthesis PP2 promotes expression of genes involved in glycosaminoglycan synthesis. Primary mouse chondrocytes were incubated for 1 to 3 days with dime-
thyl sulphoxide or the Src inhibitor PP2 (10 μmol/l), and transcript levels of genes involved in glycosaminoglycan synthesis were determined by real-
time PCR. Expression levels of (a) Xylt1, (b) Xylt2, (c) Chst3 and (d) Chst11 were significantly increased upon Src inhibition (n = 3; *P < 0.05).Arthritis Research & Therapy    Vol 9 No 5    Bursell et al.
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studies suggest that the receptor tyrosine kinases discoidin
domain receptor 2 and receptor tyrosine kinase-like orphan
receptor 2 regulate normal chondrocyte proliferation [40,41].
We have demonstrated expression of three Src kinases – Lyn,
Frk and Hck – in chondrocytes. It is likely that additional family
members are present as well. These data suggest that the
Figure 5
PP2 promotes expression of late chondrocyte marker genes PP2 promotes expression of late chondrocyte marker genes. Primary mouse chondrocytes were incubated for 1 to 3 days with dimethyl sulphoxide 
(DMSO) or the Src inhibitor PP2 (10 μmol/l), and transcript levels of late chondrocyte marker genes were determined by real-time PCR. Expression 
levels of (a) Col10a1, (b) Ihh, (c) Cdkn1c and (d) Atf3 were significantly increased upon Src inhibition (n = 3; *P < 0.05, **P < 0.01, ***P < 0.001).Available online http://arthritis-research.com/content/9/5/R105
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Figure 6
PP2 represses expression of Src kinase genes PP2 represses expression of Src kinase genes. Primary mouse 
chondrocytes were incubated for 1 to 3 days with dimethyl sulphoxide 
(DMSO) or the Src inhibitor PP2 (10 μmol/l), and transcript levels of 
Src kinase genes were determined by real-time PCR. Expression levels 
of (a) Lyn, (b) Frk and (c) Hck were significantly decreased upon Src 
inhibition (n = 3; ***P < 0.001).
Figure 7
PP2 promotes cell rounding and cortical actin formation PP2 promotes cell rounding and cortical actin formation. Primary 
mouse chondrocytes were incubated for 24 hours with (a) dimethyl sul-
phoxide or (b) the Src inhibitor PP2 (10 μmol/l), and cells were stained 
with rhodamine-phalloidin (red) for polymerized actin and with DAPI for 
nuclei (blue). PP2 induced cell rounding, loss of stress fibre, and corti-
cal organization of actin (scale bar: 2 μm).
Figure 8
PP2 promotes cell rounding and cortical actin formation PP2 promotes cell rounding and cortical actin formation. Primary 
mouse chondrocytes were incubated for 24 hours with dimethyl sul-
phoxide (DMSO) or the Src inhibitor PP2 (10 μmol/l), and cells were 
stained with antibodies against total focal adhesion kinase (FAK) or 
FAK phosphorylated on residue tyrosine 397 (green), rhodamine-phal-
loidin (red) and DAPI (blue). In the presence of DMSO, total and phos-
phorylated actin localized to focal adhesions at the end of stress fibres. 
In cells treated with PP2, total FAK acquired a diffuse cytosolic stain-
ing, whereas the signal for phosphorylated FAK was greatly reduced 
(scale bar: 2 μm).Arthritis Research & Therapy    Vol 9 No 5    Bursell et al.
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effects of PP2 observed in our experiments are due to
inhibition of multiple Src kinases. Because of overlapping
expression patterns and the well established functional redun-
dancy within the Src family, identification of the roles played by
individual family members in chondrocytes will be a major chal-
lenge and will probably require detailed analyses of knockout
mice for single or multiple Src family genes.
Several of the effects of PP2 observed here were strikingly
similar to those obtained upon inhibition of the RhoA/ROCK
pathway that we described previously [20,36,42]. For exam-
ple, inhibition of ROCK kinase activity resulted in cell rounding,
loss of stress fibres and increased expression of Sox9, colla-
gen type II and aggrecan in chondrocyte monolayer cultures.
Similarly, inhibition of ROCK activity increased the expression
of hypertrophic markers such as collagen type X in differenti-
ating chondrocytes [29]. These data suggest that RhoA/
ROCK and Src kinases could be part of the same pathway
that regulates chondrocyte differentiation. Our data show that
PP2 does not affect RhoA activity in chondrocytes, suggesting
that Src kinases do not act upstream of RhoA. ROCK inhibi-
tion caused a slight increase in the expression of Lyn and Frk
transcripts, suggesting that RhoA/ROCK does not act prima-
rily by suppressing the expression of these Src kinase genes,
at least at the RNA level. However, these data do not exclude
the possibility that the Rho pathway controls activity of Src
kinases at the post-transcriptional level. In addition, it is feasi-
ble that both signalling systems act in parallel pathways.
Experiments are under way to examine these possibilities.
Another protein that probably interacts with Src kinases in the
control of chondrocyte physiology is FAK. Our data show that
reduced FAK phosphorylation is associated with the loss of
stress fibres and cell rounding in response to PP2. FAK is a
direct substrate of Src kinases, but the residue examined
(Y397) is auto-phosphorylated by FAK in response to integrin
Figure 9
Interplay between RhoA/ROCK and Src kinase signalling Interplay between RhoA/ROCK and Src kinase signalling. (a) Primary mouse chondrocytes were incubated for 1 to 3 days with dimethyl sulphoxide 
(DMSO) or the Src inhibitor PP2 (10 μmol/l), and Ras homology A (RhoA) activity was measured using the G-LISA™ kit (Cytoskeleton). No signifi-
cant differences in RhoA activity were observed upon Src inhibition (n = 3). (b) Primary mouse chondrocytes were incubated for 1 or 2 days with 
DMSO or the Rho-associated, coiled-coil containing protein kinase (ROCK) inhibitor Y27632 (10 μmol/l) or the actin-modifying drugs cytochalasin 
D (1 μmol/l) and jasplakinolide (50 nmol/l). Expression levels of (b) Lyn, (c) Frk and (d) Hck genes were determined using real-time PCR, which 
demonstrated regulation of all three genes by the employed drugs (n = 3, *P < 0.001).Available online http://arthritis-research.com/content/9/5/R105
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engagement [43,44]. Therefore, reduced Y397 phosphoryla-
tion is not a direct effect of Src inhibition, but is secondary to
other events. Nevertheless, FAK might constitute a direct link
between Src activity and chondrocyte morphology, but this
remains to be proved. It will also be of interest to examine
whether FAK is involved in the gene expression changes
induced by PP2, because chondrocyte cell shape and gene
expression are closely linked [42].
Our results also demonstrate that several genes involved in
glycosaminoglycan synthesis (Xylt1, Xylt2, Chst3 and Chst11)
are regulated by PP2 in a manner similar to classical
chondrocyte markers such as collagen type II and aggrecan.
We observed similar co-regulation in our recent studies on
control of chondrogenesis by Rac1 [13] and C-type natriuretic
peptide [14]. These data suggest that these genes (and
potentially others that are involved in glycosaminoglycan syn-
thesis) should be included in the list of parameters investi-
gated during studies of chondrogenesis and might present
novel markers of chondrocyte differentiation.
One of the surprises of this study was the repression of Lyn,
Frk and Hck transcript levels by PP2 treatment. It therefore
appears that PP2 not only reduces the enzymatic activity of
Src kinases directly but also inhibits expression of selected
family members. It remains to be seen whether similar mecha-
nisms exist in other tissues or for additional Src kinases.
Conclusion
In summary, we have demonstrated that Src inhibition pro-
motes the chondrocyte phenotype by inducing chondrogenic
cell shape and gene expression. These data both demonstrate
physiological roles of Src family kinases in cartilage develop-
ment and homeostasis, and suggest their potential as
therapeutic targets in the treatment of skeletal diseases and in
the generation of cartilage in tissue-engineering approaches.
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